肿瘤细胞治疗研究
英文原题：Identification of cancer-specific cell surface targets for CAR-T cell therapy.
需要确定合适的细胞表面靶点，以开发新的 CAR-T 细胞。
开发新的CAR-T细胞需要确定合适的细胞表面靶点。目前，CAR-T细胞采用CD19或B细胞成熟抗原（BCMA）等谱系特异性抗原作为靶点。然而，在多数癌症中，谱系特异性抗原不能作为靶点，因为正常对应细胞也表达这些抗原，靶向它们会造成致命毒性。研究者已通过转录组分析广泛搜寻癌症特异性转录本，但报道的候选靶点很少。我们一直致力于识别肿瘤特异性抗原结构，例如多发性骨髓瘤中持续活化构象的整合素β7。近期，多位研究者开始探索逻辑门系统，使其仅在细胞表面同时表达两种抗原时才作出反应。
One should identify appropriate cell surface targets to develop new CAR-T cells. Currently, lineage-specific antigens such as CD19 or B cell maturation antigen (BCMA) are being used as targets for CAR-T cells. However, in most cancers, lineage-specific antigens cannot be used as targets because targeting normal counterparts expressing them causes fatal toxicity. Cancer-specific transcripts have been extensively searched for using transcriptome analysis, but only a few candidates were reported. We have been working on identifying tumor-specific antigen structures, for example constitutively activated conformer of integrin b7 in multiple myeloma. Recently, several researchers have been working on a logic gate system that can react only when two antigens are expressed on the cell surface.
MEMBER ACCOUNT
登录成功会直接打开下一页。
